Kimura 's disease is a rare, idiopathic condition that usually affec ts young men ofAsian descent. The disease is characterized by swelling and lesions in the head and neck region, with involvement of the subcutaneous soft tissue, major salivary glands, and lymph nodes. Patients almost always have eosinoph ilia and elevated serum immunoglobulin E levels. The diagnosis is established by biopsy. Kimura' s disease is usually self-limiting. Its etiology is unknown but is thought to be a manifestation ofan aberrant allergic response. In this paper, we describe the case of a 30-year-old patient who was diagnose d with Kimura 's disease at our institution.
Introduction
Kimura' s disease is a rare disorder that affects the subcutaneous tissue and lymph nodes. It is seen mostly in young men of Asia n descent. Clinically, Kimura' s disease can be confused with a lymphoma or infectious process, but biopsy establishes the diagnosis. We report a case of this unusual disorder at our institution in the United States.
Case report
A 30-year-old man of Asian descent presented to the Tulane Medic al Cente r in New Orleans in September 1998 with a left submandibular mass. The patient had hypertension and end-st age renal disease. He had been on peritoneal dialysis for 4 to 5 years .
The submandibular mass had first been noticed in March 1997. Fine-needle aspiration cytology at that time had revealed a mixed population of large and small lymphocytes and some histiocytes. No tumor cells had been seen. Special staining for acid-fast organisms and fungi had been negative. These findings were consistent with a reactive process.
Computed tomography (CT) of the neck in November 1997 had revealed the presence of two masses in the left submandibular region , which measured 18 and 11 mm, respectively, at the short axis. Several smaller nodes had been seen along the spinal accessory chain. The chest xray was normal. The patient was treated with antibiotics, but the lymph node enlargement had persisted. In May 1998, a repeat fine-needle aspiration biopsy had shown that the lymph ocytes-most small, but some large-were still present, and that there had been a slight increase in the number of eosi nophils.
Magnetic resonance imaging (MRI) performed in August 1998 had shown that the patient now had three sizable masses in the submandibular region; the largest dimensions of each were 3.3, 1.9, and 1.9 ern, respecti vely. Compared with the findings of the CT that had been performed 9 month s earlier, the patient' s masses had grown significantly.
The patient had mild eosinophilia (7%) in the peripheral blood and a T4ff8 ratio of 5.28. In January 1998, he had undergone a test for human immunodeficiency virus I infection, which was negative .
The patient was referred to us in September 1998, and we obtained a biopsy of the left submandibular mass. The specimen consisted of two nodul es; one measured 3 x 2.5 x 1ern and the other 1.2 x I x I em. The cut surface was tan and exhibited no areas of necrosis. Frozen-section analysis revealed an atypical follicular hyperplasia, with microabscesses and multinucleate polykaryotic cells.Flow cytometry of the lymph node tissue showed an equal proportion of T and B lymphocytes, without any detectable clon ality, and was suggestive of a reactive process. Smears and culture of the lymph node tissue were negative for bacteria , mycobacteria, and fung i.
Histology of the lymph node tissue revealed the presence of florid follicul ar hyperplasia (figure) . Many of the follicular centers exhibited necrosis with proteinaceous debris. Multinucleate polykaryocytes were prom inent in the germinal centers and in the paracort ex. Marked diffuse eosinophilia and eosinophilic abscess formation were seen. Throu ghout the paracortex, there was a diffuse sclerosis and many venules with prominent endothelial KARAVATIATHAYYIL, KRAUSE cells . There was also vascularization of the germinal centers focally . Based on these findin gs, a histologic diagno sis of Kimura's disease was made .
The patient was given a short course of steroid therapy , and his lymph adenopathy resolved. The pat ient subsequently developed focal segmental glomerulosclerosis, and he is currently bein g treated with renal dialysis. His lymphadenopathy has rem ained quie scent.
Continu ed 01/ page 199 elude inflammatory and neoplastic conditions, tuberculosis, and other infectiou s lymph node enlargements (e.g., toxopl asmo sis); Hodgkin' s disease and non-H odgkin ' s lymphoma should be primary considerations.
CT and MRI can help determine the extent and progression of the disease as well as the lymph node involvement. 12 Fine-needle aspiration cytology is helpful in some cases. 13 Although there is no one specific diagno stic feature of Kimura' s disease, a definiti ve diagnosis can made by histologic examination of the exci sed lesion . The gro ss lesion might or might not show obvious foci of necrosis. Microscopi cally , the key finding s are marked hyp erplasia with pronounced eosinophilic infilt ration. Foc i of necrosis are seen with vascul arizati on of the paracortex and deposition of hyaline material within follicles . Polyk aryotic giant cells are a common feature . Thi s combination of histologic findin gs is very characteristic of Kimura's disease. Immunostaining can show deposition of IgE in a reticular fashion between the follicl es and on the surface of nondegranulated mast cell s.1
Although the intense eosinophilia and focal necro sis are suggesti ve of a parasitic infection, no parasites have been identified. The pol ym orphou s infiltrate with eosinophilia and the presence of giant cells also raise the suspicion of Hodgkin' s disease. Thi s is especially true when the diagnosi s is attempted by fine-needle aspiration. The abs ence of Reed-Sternberg cells helps distingui sh Kimura' s disease fro m Hodgkin ' s disease.
Kimu ra 's di sease can al so be confu sed with angiol ymphoid hype rpla sia with eosinophilia (ALHE). The se two diseases have some common histologic feature s, such as eosinophilia and vascular proliferation. The distinction between the two is reviewed by Kuo et al.' ALHE, which is usually seen in older patients, manifests as multiple small dermal eruptions. Lymphadenopathy, salivary gland involvement, and elevated serum IgE levels are rare in ALHE. In ALHE, vascular structures are lined with endothelial cells that have an epithelioid or histiocytoid appearance, a feature that is lacking in Kimura' s disease. Conversely , eosinophilic follicle lysis is a char acteristic of Kimura' s disease that is not seen in ALHE. l Etiology. The etiology of Kimura' s disease is unknown . The presenc e of eosinophilia and elevated serum IgE level s sugges ts an allergic or hypersen sitivity process. No specific anti gens have been identified, but current thinkin g hold s that Kimur a' s disease is an unusu al alle rgic respon se in which Th2 cyto kine s playa part. 14.15 Treatment. Kimura' s dise ase responds well to oral steroids, but relapses often occur after treatm ent is stopped. Radiation and surgical excision are also effective .P'"! ':" The prognosis is excellent, and the disease has no pote ntial for malignancy.
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Discussion
The condition now known as Kimur a' s disease was first desc ribed in 1937 by Kim and Szeto in Chin a as an "e osinophilic hyperplastic granuloma" ; Kimura himself repo rted on the disease 1948. 1 Thi s rare disease is endemic in parts of Asia. It mainly affect s young Asian men (median age: 26 year s; male :female ratio : >3:1),1 '3 although it has been repo rted in other areas and ethnic groups .v" Disease characteristics. The most common present ation of Kimura's disease is swelling in the head and neck region. The lesion primarily involv es the subcutaneou s soft tissues of the postauricular region and sometimes the salivary glands and lymph node s. I • 2 ,7 In rare cases, it has been reported to involve other sites, such as the oral cavity, conjunctiva, eyelid, tympanic membrane, skeletal muscle, prostate, kidn ey, peripheral nerves, and epiglotti s.v-?
The onset of the Kimura' s disease is insidiou s. The amount of swelling at the affected site gradually increases over a period of months or year s. Peripheral blood eosinophili a is almo st always present. An ele vation in serum immunoglobulin E (IgE) levels has also been a consistent finding, but type I hypersensitivity is rare. Associated renal disease, characterized by proteinuria, is found in about 12% ofpatient s. IO • 11 Diagnosis. Clinicall y, the differential diagnoses in-• ,.'. .
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Figur e. Low-power view (A ) of the lymph node biopsy specimen reveals the presence offo llicular hyperplasia and proliferatin g blood vesse ls in the interfollicular region (H&E, original magnification X 40). High-p ower view (B) shows vasc ularproliferation, eosinophilic infiltration, necrosis, and the presence of polykary otic giant cells (H&E, original magnification X 400).
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PATIE T-DAYS OF THERAPY*
alagen" Tabl ts pro ide patients with effective, well-tolerated therapy. The mo t common ide effect is vesting, peciallyat high r doses. alagen Tablets do not work for e eryone , and arc contraindicated wh m uncontroll d asthma i present and when mi i . und irable .
In addition, thefollowing adverse events (;,3% incidence) were reported at dosages of 15-30 mg/day in the controlled ciinical trials: Headache (11 %),dyspepsia (7%), lacrimation (6%), edema (5%), abdominal pai n (4%), amblyopia (4%), vomiting (4%), pharyngitis (3%), hypertension (3%).
The following events were reported with treated head and neck cancer patients at incidences of 1% to 2% at dosages of 7.5 to 30 mg/day: abnormal vision, conjunctivitis, dysphagia, epistaxis, myalgias, pruritus, rash, sinusitis, tachycardia, taste perversion, tremor, voice alteration.
The following events were reported rarely in treated head andneck cancer patients (<1%) : Causal relation is unknown.
Body odor, hypothermia, mucous membrane abnormality,bradycardia, ECG abnormality, palpitations, syncope, anorexia, increased appetite, esophagitis, gastrointestinal disorder, tong ue disorder , leukopenia, iymphadenopathy, anxiety, confusion, depression, abnormal dreams, hyperkinesia, hypoesthesia, nervousness, paresthesias, speech disorder, twitching, increased sputum, stridor, yawning, seborrhea, deafness, eye pain, glaucoma, dysuria, metrorrhagia, urinary impairment.
Inlong-term treatment were twopatients withunderlying cardiovascular disease of whom one experienced a myocardial infarct and another an episode of syncope.The association withdrug is uncertain.
Siooren's Svndrome Patients: In controlled studies, 376patients received pilocarpine, of whom 5% were men and 95% were women. Race distribution was84%Caucasian, 9%Oriental, 3%Black, and 4%ofother origin. Mean age was55 years. The majority of patients were between 40 and 69 years (70%), 16% were 70 years and older and 14%were younger than40years ofage. Ofthese patients, 161/629 (89/376 receiving pilocarpine) were over theage of 65years.The adverse events reported bythose over 65years andthose 65years and younger were comparable except fornotabletrends forurinaryfrequency, diarrhea, and dizziness.The incidences of urinary frequency and diarrhea in theelderly were about double those in the non-elderly. The incidence of dizziness wasabout three times as high in the elderly as in the non-elderly. These adverse experiences were not considered to be serious. In the 2 placebocontrolledstudies, themost common adverse events related to drug use were sweating, urinary frequency,chills, and vasodilatation (flushing).The mostcommonly reported reason forpatient discontinuation of treatment wassweating. Expected pharmacologic effects ofpilocarpine incl ude the following adverse experiences associated withSALAGEN' Tablets:
MGlPHARMA,lNC. 8IooTlirv;jtoo,MN55438-2318~~.
Inaddition,thefollowing adverse events (;,3% incidence) were reported at dosing of 20mg/day in thecontrolled ciinicai triais: Headache (13%), flu syndrome (9%), dyspepsia (7%), dizziness (6%), pain (4%), sinusitis (4%), abdominal pain (3%), pharyngitis (2%), rash (2%), infection (2%). The following events were reported in Sjogren's patients at incidences of 1% to 2%at dosing of 20mg/day: accidental Injury, allergicreaction, back pai n,blurred vision, constipation, increased cough, edema, epistaxis, face edema, fever, flatulence, glossitis, labtest abnormaiities including chemistry, hematology, and urinalysis, myalgia, palpitation, pruritus, somnolence, stomatitis, tachycardia, tinnitus, urinary incontinence, urinary tractinfection, vaginitis, vomiting. The following events were reported rarely in treated Sjogren's patients ( The following adverse experiences have been reported rarely withocular pilocarpine: A-V block, agitation, ciliary congestion, confusion, delusion, depression, dermatitis, middle ear disturbance, eyeiid twitching, maiignant glaucoma, iriscysts, macular hole, shock, and visual hallucination. MANAGEMENT OF OVERDOSE: Fatal overdosage withpilocarpine has been reported inthescientific iiterature at doses presumed tobegreater than 100 mg in two hospitaiized patients. 100 mg of pilocarpine is considered potentially fatal. Overdosage should betreated withatropine titration (0.5mg to 1.0 mggiven subcutaneously or intravenously) and supportive measures tomai ntain respiration and circulation. Epinephrine (0.3 mg to 1.0 mg, subcutaneously or intramuscularly) may also be of value in the presence of severe cardiovascular depression or bronchoconstriction. It is notknown if pilocarpine is dialyzable. DOSAGEAND AD MINISTRATION: Head & Neck Cancer Patients' The recommended initialdose of SALAGEN" Tablets is one tablet (5mg) taken three times a day . Dosage should be titrated according to therapeuticresponse and tolerance.The usual dosage range is upto 3-6 tablets or15-30mgper day. (Not to exceed 2 tablets perdose.)Although early improvement may bereaiized, at least 12weeks of uninterrupted therapy withSALAGEN' Tablets may benecessary to assess whether a beneficial response willbeachieved.The incidence ofthemost common adverse eventsincreases withdose.The lowest dose thatIstolerated and effectiveshould be used for maintenance. Sjogren'sSyndromePatients: Pregnancy: Teratogenic effects. Pregnancy Category C: Pilocarpine wasassociated witha reduction in themean fetal body weight and anincrease in theincidence of skeletal variations when given to pregnant rats at a dosage of 90 mglkg/day (approximately 26 times themaximum recommended dose fora 50 kg human when compared on the basis of body surface area (mg/mẽ stimates).These effects may have been secondary tomaternal toxicity. Inanother study, oral administration of pilocarpine to female rats during gestation and lactation at a dosage of 36 mglkg/day (approximately 10 times the maximum recommended dose for a 50 kg human when compared onthebasis of body surface area (mg/m~estimates) resulted in anincreased incidence of stillbirths; decreased neonatal survival and reduced mean body weight of pups were observed at dosages of 18 mglkg/day (appronmately 5times themaximum recommended dose for a 50 kg human when compared on the basis of body surface area (mg/m~estimates) and above.There arenoadequate and well-controlled studies in pregnant women. SALAGEN' Tablets should be used during pregnancy onlyif thepotential benefit justifies the potential riskto the fetus. Nursing Mothers: It is not known whether this drug is excreted in humanmilk. Because many drugs areexcreted inhuman milkand because of the potential for serious adverse reactions in nursing infants from SALAGEN" Tablets, a decision should be made whether to discontinue nursing orto discontinue thedrug, taking intoaccount theimportance of thedrug to themother.
Pediatric Use: Safety and effectiveness in pediatric patients have not been estabiished.
Geriatric Use: Head and Neck Cancer Patients· Intheplacebo-controlled ciinical trials (see Ciinical Studies section in full prescribinginformation) themean ageof patients wasapproximately 58years (range 19to80) . Of these patients, 97/369 (61/217 receiving pilocarpine) were over theage of 65years. Inthehealthy volunteer sfudies, IS/ISOsubjects were over theage of 65years. Inboth study populations, theadverse events reported bythose over 65years and those 65years andyounger were comparable. Ofthe15elderly vol unteers (5 women, 10 men), the5 women had higher Cmax's and AUC's than themen. Sjogren's Syndrome patients: Intheplacebo-controlledcii nical trials, the mean age of patients wasapproximately 55 years (range 21 to 85) .The adverse events reported bythose over 65yearsand those 65years and younger were comparable except fornotable trends foruri nary frequency, diarrhea, and dizziness (see ADVERSEREACTIONS section).
ADVERSE REACTIONS: Head & Neck Cancer patients· In controlled studies, 217patients received pilocarpine, of whom 68% weremen and 32%were women. Race distributionwas91%Caucasian, 8%Black, and 1%ofother origin. Mean age wasapproximately 5Byears.The majority of patientswerebetween 50and 64years (51 %),33%were 65years and older and 16%were younger than 50 years of age.
The most frequent adverse experiences associated withSALAGEN' Tablets were a consequence oftheexpected pharmacologic effects ofpilocarpine. Pulmonary Disease: Pilocarpine hasbeen reported to increase airway resistance, bronchial smooth muscle tone, and bronchial secretions. Pilocarpine hydrochloride should be administered with caution to and under close medical supervision in patients withcontrolled asthma, chronic bronchitis, or chronic obstructive pulmonary disease requiring pharmacotherapy.
PRECAUTIONS:
General: Pi locarpine toxicity is characterized byanexaggeration of its parasympathomimetic effects. These may incl ude: headache, visual disturbance, lacrimation, sweating, respiratory distress, gastrointestinal spasm, nausea, vomiting, diarrhea, atrioventricuiar block, tachycardia, bradycardia, hypotension, hypertension, shock, mental confusion, cardiac arrhythmia, and tremors.
The dose-related cardiovascular pharmacologic effects of pilocarpine include hypotension, hypertension, bradycardia, and tachycardia.
Pilocarpine should beadministered withcaution topatients withknown or suspected choielithiasis or biliary tract disease. Contractions of the gallbladder or biliary smooth muscle could precipitate compiications including choiecystitis, cholangitis, and biliary obstruction.
Pilocarpine may increase ureteral smooth muscle tone and could theoretically precipitate renal colic (or"ureteral reflux"), particularly in patients withnephrolithiasis. DrugInteractions: Pilocarpine should beadministered withcaution to patients taking beta adrenergicantagonists because of the possibility of conduction disturbances. Drugs with parasympathomimetic effects administered concurrently withpilocarpine would beexpected to resuit in additive pharmacologic effects. Pi locarpine might antagonize the anticholinergic effects ofdrugs used concomitantly.These effects should be considered when antichoiinergic properties may be contributing to thetherapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium).
While no formal drug interaction studies have been performed, the following concomitant drugs were used inat least 10%ofpatients ineither or both Sjogren's efficacy studies: acetylsaiicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. Carcinogenesis, Mutagenesis, Impairment of Fertili ty: Nodefinitive long term animal studies have evaluated the carcinogenic potential of pilocarpine. Noevidence thatpilocarpine hasthepotential tocause genetic toxicity was obtained in a series of studies that Included: 1) bacterial assays (Salmonella and E.coli) forreverse gene mutations; 2)an in vitro chromosome aberration assay in a Chinese hamster ovary celliine; 3)an in vivo chromosome aberration assay (micronucleus test) in mice; and 4) a primary DNA damage assay (unscheduled DNA synthesis) in rat hepatocyte primary cultures.
Oral administration of pilocarpine to male and female rats ata dosage of 18mglkg/day (appronrnately 5 times themaximum recommended dose for a 50 kg human when compared on thebasis of body surface area (mg/m~estimates) resulted in impairedreproductive function, including reduced fertility, decreased sperm motility,and morphologic evidence of abnormal sperm. It isunclear whether thereduction infertiiity was due to effects on male animals,female animals, or both males and females. In dogs, exposure to pilocarpine at a dosage of 3 mglkg/day (approximately 3 times the maximum recommended dose for a 50 kg human when compared on the basis of body surface area (mg/m~estimates) for six months resulted in evidence of impaired spermatogenesis. The data obtained in these studies suggest thatpilocarpine may impair thefertility of male andfemale humans.
SALAGEN" Tablets should be administered to individuals who are attempting to conceive a child only if the potential benefit justifies potential impairment offertility.
KIMURA 'S DISEASE : A CA SE REPORT

